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The increased use of molecular identification methods and mass spectrometry has
revealed that Acinetobacter spp. of the A. baumannii (Ab) group other than A. baumannii
are increasingly being recovered from human samples and may pose a health challenge
if neglected. In this study 76 isolates of 5 species within the Ab group (A. baumannii
n = 16, A. lactucae n = 12, A. nosocomialis n = 16, A. pittii n = 20, and A. seifertii n = 12),
were compared in terms of antimicrobial susceptibility, carriage of intrinsic resistance
genes, biofilm formation, and the ability to kill Caenorhabditis elegans in an infection
assay. In agreement with previous studies, antimicrobial resistance was common among
A. baumannii while all other species were generally more susceptible. Carriage of genes
encoding different efflux pumps was frequent in all species and the presence of intrinsic
class D β-lactamases was reported in A. baumannii, A. lactucae (heterotypic synonym of
A. dijkshoorniae) and A. pittii but not in A. nosocomialis and A. seifertii. A. baumannii and
A. nosocomialis presented weaker pathogenicity in our in vitro and in vivo models than
A. seifertii, A. pittii and, especially, A. lactucae. Isolates from the former species showed
decreased biofilm formation and required a longer time to kill C. elegans nematodes.
These results suggest relevant differences in terms of antibiotic susceptibility patterns
among the members of the Ab group as well as highlight a higher pathogenicity potential
for the emerging species of the group in this particular model. Nevertheless, the impact
of such potential in the human host still remains to be determined.
Keywords: Acinetobacter, multi-drug resistance, virulence, biofilm formation, C. elegans, efflux pumps,
oxacillinases
INTRODUCTION
Among the 62 validly named Acinetobacter species (List of Prokaryotic Names with
Standing Nomenclature1, last accessed April 2019), Acinetobacter baumannii has, for many
years, monopolized our attention. Responsible for bloodstream infections, ventilator-associated
pneumonia, wound infections, and meningitis, among other infections, A. baumannii excels in
1http://www.bacterio.net/acinetobacter.html
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its ability to persist and survive in the nosocomial setting (Peleg
et al., 2008). In comparison, little is known regarding the closely
related members of the so-called A. baumannii (Ab) group, such
as Acinetobacter nosocomialis and Acinetobacter pittii, previously
known members of the group, but also Acinetobacter lactucae
(heterotypic synonym of A. dijkshoorniae) and Acinetobacter
seifertii, whose species status has recently been acknowledged
(Nemec et al., 2015; Cosgaya et al., 2016). Species other than
A. baumannii among the Ab group are increasingly being
isolated from human specimens, albeit not as frequently as
A. baumannii, and they also possess an undeniable ability to cause
disease (Espinal et al., 2011; Schleicher et al., 2013; Chen et al.,
2018; Pailhories et al., 2018; Rocha et al., 2018). Unfortunately,
they are often erroneously identified as A. baumannii by
common phenotypic methods such as biochemical tests and
semi-automated identification systems, thus underestimating
their true prevalence and clinical relevance. Accurate species
identification is achieved by molecular methods, such as ARDRA,
rpoB and gyrB sequence analysis, Pasteur MLST scheme-based
identification, whole genome sequencing (Vaneechoutte et al.,
1995; Gundi et al., 2009; Diancourt et al., 2010; Higgins
et al., 2010b; Fitzpatrick et al., 2016) and, more recently, mass
spectrometry (Mari-Almirall et al., 2017).
Antimicrobial resistance studies containing information about
A. lactucae, A. nosocomialis, A. pittii and A. seifertii are scarce,
although existing data support their general susceptibility to most
antibiotics (Chuang et al., 2011; Lai et al., 2012; Chen et al., 2018;
Pailhories et al., 2018). In contrast, A. baumannii is considered
a problem pathogen because of its frequently reported multi-
drug resistant (MDR) phenotype. This pathogen has developed
resistance to all antibiotics, including last resort antibiotics such
as carbapenems, tigecycline and colistin (Roca et al., 2012; Nowak
et al., 2017). Multi-drug resistance represents one of the best
assets of A. baumannii and may account for its success in the
hospital setting; nonetheless other pathogenic attributes may as
well impact its ability to infect the host.
Likewise, there is plenty of information on the virulence
traits of A. baumannii (Harding et al., 2018) but little is known
regarding the other members of the Ab group. Studies regarding
the virulence attributes of different Acinetobacter species are
rare, and usually include only a few isolates (de Breij et al.,
2010; Bitrian et al., 2012; Peleg et al., 2012; Kinsella et al.,
2017) or are limited to bacteremic isolates from a unique region
(Na et al., 2016). Noticeably, none of the abovementioned
studies include information about A. lactucae and there is
just one report that highlights its ability to cause disease and
carry genetic determinants conferring carbapenem resistance
(Espinal et al., 2015).
A few reports have suggested relevant differences in the
clinical outcomes of infections caused by former members of
the Ab group (Chuang et al., 2011; Wisplinghoff et al., 2012;
Lee et al., 2013; Chusri et al., 2014), suggesting that, in order to
understand the clinical relevance and the virulence potential of
closely relatedAcinetobacter spp., further studies on susceptibility
patterns and pathogenesis need to address them as distinct
entities rather than as a homogeneous group. In this work we
have gathered a collection of representative isolates from all five
known Acinetobacter species of the Ab group and compared
their antibiotic susceptibility profiles and carriage of resistance
determinants as well as their pathogenic potential using both
in vitro and in vivo assays.
MATERIALS AND METHODS
Bacterial Strains, Culture Conditions,
and Epidemiologic Characterization
Isolates used in this study belong to Acinetobacter baumannii
(n = 16), A. lactucae (n = 12), A. nosocomialis (n = 16), A. pittii
(n = 20) and A. seifertii (n = 12) (Supplementary Data Sheet S1).
Species identification was performed by matrix-assisted laser
desorption ionization-time of flight mass spectrometry (Mari-
Almirall et al., 2017). The clonal relatedness was established
either by repetitive element palindromic PCR (REP-PCR) or
by pulsed-field gel electrophoresis (PFGE) of ApaI-digested
DNA (Seifert et al., 2005). The sequence type (ST) was
determined following the Pasteur multilocus sequence typing
(MLST) scheme, as previously described (Diancourt et al., 2010).
Bacterial cultures were routinely grown on Columbia sheep blood
agar (Becton Dickinson, Heidelberg, Germany) at 37◦C, unless
stated otherwise.
Antimicrobial Susceptibility Testing and
Presence of Acquired Resistance Genes
The minimum inhibitory concentration (MIC) was determined
by broth microdilution or gradient diffusion (AB bioMérieux,
Solna, Sweeden) in Mueller Hinton II broth (CONDA, Madrid,
Spain) or agar plates (Becton Dickinson, Heidelberg, Germany),
respectively, and interpreted according to EUCAST guidelines
when appropriate (EUCAST clinical breakpoints version 8.0,
2018). As no EUCAST susceptibility breakpoint for ceftazidime
is available, the corresponding clinical breakpoint according
to CLSI guidelines was used instead (susceptible ≤ 8 µg/mL,
resistant ≥ 32 µg/mL; CLSI supplement M100-S28, 2018). The
antibiotics tested were amikacin, ceftazidime, ciprofloxacin,
colistin, gentamicin, imipenem, meropenem, tigecycline,
and tobramycin. Presence of metallo-β-lactamases, blaKPC,
blaOXA-23, blaOXA-24/40, and blaOXA-58 genes was determined
by multiplex PCR (Bogaerts et al., 2013) or characterized in
previous studies (Supplementary Data Sheet S1).
Detection of Genes Potentially
Associated With Intrinsic Resistance
The presence of genes encoding eﬄux pumps from the
resistance-nodulation-cell division (RND) family (adeABC,
adeDE, adeFGH, and adeIJK), and intrinsic oxacillinases (OXA)
from the class D β-lactamases was evaluated by PCR using the
primers listed in Supplementary Table S1. In silico analysis
of available genomic sequences at NCBI were performed in
order to ensure amplification in all the Ab group species,
otherwise, species-specific primers were designed. At the time
of the analysis, only one A. seifertii genome and only two
A. lactucae genomes were available at the NCBI databases.
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Intrinsic OXA β-lactamases were analyzed by DNA sequencing
and cluster analysis of partial amino acid sequences (residues
9 to 267) using the MEGA version 6 software (Tamura et al.,
2013). Briefly, sequences were aligned using MUSCLE (Edgar,
2004) and unrooted phylogenetic trees were constructed using
the neighbor-joining method with bootstrap values based on
1000 replicates, with software default settings. When necessary,
additional sequences were retrieved from public databases. The
partial sequences of allelic variants used for cluster analysis are
provided in the Supplementary Data Sheet S2.
Quantitative Biofilm Formation Assay
Biofilm formation was assessed in non-treated 96-well
polystyrene microtiter plates. Bacteria were grown overnight
at 37◦C with shaking in modified M63 medium consisting of
KH2PO4 (12 g/l), K2HPO4 (7 g/l), (NH4)2SO4 (2 g/l), adjusted
to pH 7 with KOH prior to autoclaving, and supplemented
with glucose (0.2% w/v), MgSO4 (1 mM) and casaminoacids
(0.5% w/v). Overnight cultures were adjusted to an OD600
of 0.1 and diluted 1:10 in modified M63 medium. For each
isolate four wells were inoculated with 150 µL of the former
suspension. Afterward, plates were incubated statically at 28
or 37◦C. After 44 h, supernatants were removed with a 20 G
needle, wells were washed once with PBS, and biofilm was
fixed with methanol 99% for 10 min and evaporated at 65◦C
for 20 min. Biofilm was stained with crystal violet 2% for
20 min. Glacial acetic acid 33% was used to solubilize the dye
and absorbance was recorded at 580 nm. The OD580/OD600
ratio was used to quantify biofilm formation and to normalize
for bacterial growth differences. At least three biological
replicas with a covariance for the OD580/OD600 ratio less
than 45% were performed for each isolate. Isolates were
considered biofilm producers when the OD580/OD600 ratio
was greater than 1. Appropriate controls were added for all
assays and all plates, and consisted of bacteria-free media and
the inclusion of A. baumannii ATCC 19606 and A. baumannii
ATCC 17978 bacterial strains as strong and weak biofilm
producers, respectively.
Surface-Associated Motility Assay
Motility plates consisted of tryptone (5 g/L), NaCl (2.5 g/L) and
agarose (0.3% w/v) (CONDA, Madrid, Spain). Prior to pouring,
media was cooled down to 50◦C in a water bath. Twenty mL
were dispensed in 90 mm diameter petri dishes and allowed to
solidify for 45 min plus an additional 15 min for air-drying in a
biosafety cabinet. Then, 1 µL of the same bacterial suspension
used for biofilm assays was inoculated onto the center of the
surface of the media, plates were sealed with parafilm and
incubated at 37◦C for 18 h. Isolates tended to grow concentrically
from the inoculation point, thus surface-associated motility was
recorded as the mean value (cm) of three diameter measurements
per plate. Isolates were considered motile when the diameter
exceeded 1 cm. In every assay, isolates were tested in duplicate,
and at least four biological replicates were performed for all
the isolates. In all the assays, A. baumannii ATCC 19606 and
A. baumannii ATCC 17978 were used as non-motile and motile
control strains, respectively.
Caenorhabditis elegans Killing Assays
The Fer-15 line of C. elegans, fertile at 15◦C but not at 25◦C and
provided by the Caenorhabditis Genetics Center, was used for the
infection model. Nematodes were routinely maintained at 15◦C
and fed with the non-virulent E. coli OP50 strain in Nematode
Growth Medium agar. Assays were performed using L4 stage
worms as previously described (Espinal et al., 2019). Live worms
were scored every day for 15 days using a stereomicroscope.
Worms were considered dead when unresponsive to touch and
immotile for more than 20 s. The lethal time 50% (LT50), that is,
the time (days) needed to kill 50% of the worms, of each isolate
in each assay was obtained by extrapolation from the sigmoidal
regression of the killing curves (R2 > 0.95) using GraphPad
Prism version 5 for Windows (GrapPad Software, La Jolla, CA,
United States). At least three biological replicates were performed
for each isolate. In all the assays, E. coli OP50 was used as a
non-virulent control strain.
Statistical Analysis
All statistical analyses were performed using IBM SPSS
Statistics for Windows, version 23 (IBM, Corp., Armonk, NY,
United States). Kolmogorov–Smirnov test or Shapiro–Wilk test
was used to assess normal distribution when n > 30 or n < 30,
respectively. For the regression models, the Pearson correlation
coefficient was determined when the variables followed a normal
distribution. Whenever non-normally distributed variables or
ordinal variables were analyzed, the Spearman rank correlation
coefficient or the Kendall’s τ correlation coefficient were
calculated, respectively. The Kruskal–Wallis test was performed
to compare the distribution of variables among the different
species; post hoc analyses were automatically performed by
the software. Pairwise differences were compared using Mann–
Whitney U-test. The Wilcoxon signed rank test was used to
compare biofilm formation at 28 and 37◦C using quantitative
data, whereas the McNemar test was used to compare the
proportions of biofilm-producing isolates at both temperatures.
For all tests performed, P-values < 0.05 were considered to be
statistically significant.
Ethics Statement
The experimental procedures described in this work do not
involve the usage of biological samples from humans or animals.
Clinical bacterial isolates studied here were obtained from
clinical collections at several microbiology labs where they were
initially recovered from clinical samples used for microbiological
diagnosis. Informed consent was, therefore, not required. The
protocol for this study was approved by the Ethics Committee
on Clinical Research (CEIC) of the Hospital Clinic de Barcelona
(HCB/2014/0499, HCB/2017/0923, and HCB/2017/0833).
RESULTS
Antimicrobial Susceptibility Profiles
We have characterized the susceptibility patterns of 76 isolates
from 5 different Acinetobacter species within the Ab group,
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as shown in Table 1. Isolates other than A. baumannii were
usually susceptible to almost all antibiotics tested, with only
a few exceptions. The A. seifertii isolates from our collection
were susceptible to all the agents tested, thus constituting the
species with the lowest rates of resistance. Likewise, isolates
of A. nosocomialis were susceptible to all agents except the
aminoglycosides, for which rates of resistance were 25% for
gentamicin and 5% for amikacin.
Carbapenem-resistance was identified in three A. pittii isolates
and one A. lactucae isolate, and was associated with the presence
of genes encoding New Delhi metallo-β-lactamase (NDM) or
OXA-type enzymes (Supplementary Data Sheet S1). A. pittii
and A. lactucae isolates, however, tested susceptible to almost
all other antimicrobial agents but ceftazidime, with rates of
resistance of 5 and 25%, respectively. One A. pittii isolate was
resistant to ciprofloxacin (MIC> 32 µg/mL) and another isolate
of the same species was also resistant to gentamicin (MIC of
6 µg/mL). In contrast, A. baumannii isolates presented higher
rates of resistance (75% for ceftazidime, 68.8% for ciprofloxacin
and gentamicin, 62.5% for imipenem, 56.3% for tobramycin,
43.8% for meropenem, and 31.5% for amikacin), and resistance
to carbapenems was usually associated with the production of
OXA-type carbapenemases (Supplementary Data Sheet S1).
Non-susceptibility to at least one agent in all but two or fewer
antimicrobial categories, i.e., XDR (Magiorakos et al., 2012), was
determined in 68.75% of A. baumannii isolates, the NDM-1
producing A. pittii was resistant to three or more antimicrobial
agents from different categories, i.e., MDR and all other isolates
TABLE 1 | Antimicrobial susceptibility profiles of the Ab group species.
Antimicrobial A. baumannii (n = 16) A. lactucae (n = 12) A. nosocomialis (n = 16) A. pittii (n = 20) A. seifertii (n = 12)
Amikacin MIC50 4 0.75 1.5 1.5 1
MIC90 128 1.5 6 4 2
Range 0.38–>256 0.38–3 1–12 0.75–24 0.5–12
R(%) 31.3 0 5 0 0
Ceftazidime MIC50 128 3 3 3 4
MIC90 >128 32 4 16 6
Range 2–>128 2–>256 1.5–4 1.5–>256 2–12
R(%)a 75 25 0 5 0
Ciprofloxacin MIC50 64 0.25 0.0125 0.19 0.25
MIC90 >64 0.38 0.5 0.5 0.38
Range 0.094–>64 0.19–0.38 0.064–0.75 0.125–>32 0.064–0.75
R(%) 68.85 0 0 5 0
Colistin MIC50 0.38 0.25 0.19 0.19 0.125
MIC90 1 0.38 0.38 0.5 0.25
Range 0.38–8 0.19–0.38 0.38–0.5 0.19–1 0.125–0.38
R(%) 6.3 0 0 0 0
Gentamicin MIC50 32 0.38 0.75 0.38 0.25
MIC90 >64 0.5 8 4 1
Range 0.25–>256 0.25–0.75 0.38–12 0.19–6 0.094–3
R(%) 68.8 0 25 5 0
Imipenem MIC50 16 0.25 0.25 0.38 0.25
MIC90 64 0.38 0.25 >32 0.25
Range 0.38–>64 0.094–>32 0.19–0.38 0.25–>32 0.125–1.5
R(%) 62.5 8.3 0 15 0
Meropenem MIC50 8 0.25 0.25 0.75 0.5
MIC90 >64 0.38 0.5 >32 0.75
Range 0.25–>64 0.125–>32 0.19–0.5 0.25–>32 0.25–1.5
R(%) 43.8 8.3 0 15 0
Tigecycline MIC50 1 0.19 0.19 0.19 0.19
MIC90 2 0.25 1.5 0.75 0.25
Range 0.19–2 0.125–0.75 0.125–2 0.094–2 0.094–1
R(%)b ND ND ND ND ND
Tobramycin MIC50 8 0.38 0.38 0.38 0.25
MIC90 >64 0.38 2 1.5 0.38
Range 0.38–96 0.19–0.38 0.25–3 0.19–2 0.094–1.5
R(%) 56.3 0 0 0 0
R(%), percentage of resistant isolates. MICs are expressed in µg/mL. ND, not determined; aClinical breakpoint according to CLSI guidelines; bNo clinical
breakpoints available.
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were overall considered as highly susceptible. Finally, all the
species of the Ab group showed low MIC values of tigecycline
(Table 1) and, among all the isolates of the Ab group, only
one A. baumannii isolate was resistant to colistin with an MIC
of 8 µg/mL.
Distribution of RND Efflux Pumps and
Presence of Intrinsic blaOXA Genes
The occurrence of the different RND eﬄux pumps in the species
of the Ab group is shown in Figures 1A–D. All isolates encoded at
least one of the RND eﬄux systems known to be associated with
antimicrobial resistance, and it was common to detect three or
even four different eﬄux pumps in isolates from all Acinetobacter
species (Supplementary Data Sheet S1). adeG and adeJ genes
were identified in all species and were commonly present in most
isolates (80 to 100 and 50 to 100%, respectively). adeE was highly
disseminated within A. nosocomialis (100%) and A. pittii (90%),
and was also present in 75% of A. seifertii isolates. However, adeE
was found in only one isolate of A. lactucae and it was missing
in A. baumannii. The adeB gene, on the other hand, was absent
in A. seifertii but was ubiquitous in A. baumannii (93.75%) and
A. nosocomialis (100%). Interestingly, isolates from A. pittii and
A. lactucae carried a distinct adeB-like gene with 75 and 86%
similarity to the adeB gene from A. baumannii, respectively. This
gene was present in 90 and 66.7% of A. pittii and A. lactucae
isolates, respectively.
In addition to the presence of different RND eﬄux pumps,
we also evaluated the carriage of genes encoding intrinsic
OXA enzymes. Intrinsic blaOXA genes were reported in all
A. baumannii, A. lactucae and 16 out of 20 A. pittii isolates but
we were not able to detect them in any of the A. nosocomialis and
A. seifertii isolates.
Cluster analysis of all sequences revealed that the OXA
variants harbored by members of each of the three Acinetobacter
species clustered together with high bootstrap values (Figure 2),
the only exception being the intrinsic OXA β-lactamase of the
A. lactucae RUH-14531 isolate that clustered together with OXA
sequences from A. pittii.
Biofilm Formation at 28 and 37◦C
Biofilm formation values at both 28 and 37◦C showed a high
degree of variability among isolates of each of the five different
Acinetobacter species included in the study (Figure 3A). No
relevant differences in growth yields were observed among the
different species or among members of the same species.
Nevertheless, statistically significant differences were
observed between some species at each temperature; A. lactucae
formed significantly more biofilm than A. baumannii at both
temperatures and than A. nosocomialis at 37◦C (Kruskal–Wallis
test, post hoc P-value of 0.009, 0.001, and 0.004, respectively); and
A. pittii and A. seifertii produced significantly more biofilm than
A. baumannii at 37◦C (Kruskal–Wallis test, post hoc P-values of
0.024 and 0.035, respectively). Despite the high dispersion of the
data, and thus the lack of statistical significant differences for
most pairwise comparisons, there were a few observations worth
mentioning. A. baumannii isolates tended to form less biofilm
than those of the other species, and biofilm formation was similar
between A. lactucae, A. pittii and A. seifertii. Likewise, biofilm
formation in A. nosocomialis resembled that of Ab group species
other than A. baumannii at 28◦C, but at 37◦C it was comparable
to that of A. baumannii.
Similar trends were observed when classifying isolates as
biofilm producers and non-producers (Figure 3B). Our results
showed that all A. lactucae isolates produced biofilm at both
temperatures, and that the genetically related A. pittii species
also presented a high proportion of biofilm-producing isolates
FIGURE 1 | Occurrence of the genes encoding efflux pumps in the Ab group
(A) adeABC, (B) adeDE, (C) adeFGH, and (D) adeIJK.
FIGURE 2 | Cluster analysis of A. baumannii, A. lactucae, and A. pittii based
on the partial amino acid sequence of their intrinsic OXA β-lactamases.
Bootstrap values (%) are indicated in the branches. The scale bar indicates
sequence divergence. The allele of A. lactucae clustering with those from
A. pittii is highlighted in yellow. ST, sequence type; ND, not determined.
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FIGURE 3 | Biofilm formation at 28 and 37◦C of the Ab group species. (A) Overlapping dot plot and box plot of the biofilm formation values of each species at 28
and 37◦C. The boxes span from the first to the third quartile. The median is indicated as a segment inside the box. Whiskers indicate the minimum and maximum
biofilm formation values. Each dot corresponds to the average biofilm formation value of an isolate after at least three biological replicates. Statistically significant
differences upon temperature shift (Wilcoxon signed rank test) and between species (Kruskal–Wallis and post hoc tests) are highlighted with asterisks: (∗) if the
P-value < 0.05, (∗∗) if the P-value ≤ 0.01, and (∗∗∗) if the P-value ≤ 0.001. (B) Percentage of biofilm-producing isolates of each species at 28 and 37◦C. Isolates
were considered as biofilm producers when the biofilm formation value was greater than 1. Statistically significant differences upon temperature shift (McNemar test)
are highlighted with asterisks: (∗) if the P-value < 0.05 and (∗∗) if the P-value ≤ 0.01.
FIGURE 4 | Surface associated motility in the Ab group species. Overlapping
dot plot and box plot of the surface-associated motility of each species.
Surface-associated motility was recorded as the diameter of growth after 18 h
of incubation at 37◦C using tryptone (5 g/L), NaCl (2.5 g/L), and agarose
(0.3% w/v) motility media. The boxes span from the first to the third quartile.
The median is indicated as a segment inside the box. Whiskers indicate the
minimum and maximum diameters measured. Each dot corresponds to the
average diameter measured for an isolate after at least four biological
replicates. Statistically significant differences were not found (Kruskal–Wallis
test, P-value > 0.05).
(90%). In contrast, A. baumannii was the species with the least
amount of biofilm-producing isolates, 50% or less, depending
on the temperature. Also, upon shifting the temperature from
28 to 37◦C, a reduction in the number of biofilm-producing
isolates was observed in A. baumannii, A. nosocomialis and
A. seifertii, while the number of biofilm-producing isolates
remained unchanged in A. lactucae and A. pittii. Although this
reduction was not statistically significant for A. baumannii and
A. seifertii (from 50 to 43.8%, and from 83.3 to 75%, respectively),
the effect of the temperature was greater in A. nosocomialis,
in which shifting the temperature from 28 to 37◦C decreased
the percentage of biofilm-producing isolates from 93.8 to 43.8%
(Figure 3B, McNemar test, P-value of 0.008). Thus, and under
our experimental conditions, half of the isolates of this species
were able to develop biofilm at 28◦C but not at 37◦C, and even
in those isolates that did not lose the ability to produce biofilm
at 37◦C, a net reduction in the biofilm formation values was
observed (Wilcoxon rank sum test, P-value of 0.01). On the
other hand, the biofilm formation values of A. lactucae and
A. pittii isolates were higher at 37◦C than at 28◦C (Wilcoxon
rank sum test, P-value of 0.002 and 0.005, respectively; up to
2.3 fold changes, data not shown), although we did not detect
biofilm non-producing isolates at 28◦C turning into biofilm-
producers at 37◦C.
Surface-Associated Motility Across
Species of the Ab Group
In our collection, surface-associated motility was observed in
isolates of all the species studied, with greater intra-species
variability for A. baumannii, A. nosocomialis and A. seifertii
isolates (mean values± SD (cm) of 2.315± 1.722, 2.078± 1.775,
and 3.188± 1.755, respectively), than for A. pittii and A. lactucae
(2.717 ± 0.829 and 1.653 ± 0.844, respectively) (Figure 4).
Overall, differences in the distribution of surface-associated
motility between species were not detected when taking into
account the extent of motility. However, classification of the
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isolates into motile vs. non-motile according to the individual
degree of motility showed higher rates of motility in A. pittii
(95%) and A. lactucae (83.3%), followed by A. seifertii and
A. baumannii (75 and 62.5%, respectively). A. nosocomialis was
the least motile species of the group under the conditions tested
with only half of the isolates being motile. Interestingly, rates
of motility resembled those described above regarding biofilm
formation at 37◦C for A. nosocomialis. There was a positive
correlation between motility and biofilm formation at 37◦C in
all species except for A. pittii (Spearman’s correlation coefficients
between 0.622 and 0.7128, and P-values of 0.006 to 0.033),
meaning that, in general, the more motile an isolate was, the more
biofilm it tended to produce.
Interestingly, we also observed that all isolates displayed
different surface-associated motility morphotypes, as previously
described forA. baumannii (Skiebe et al., 2012), in a rather strain-
specific than species-specific manner. A part from non-motile
isolates (morphotype A), four additional different morphotypes
(B, C, D and E, in order of abundance) were defined: morphotype
B presented striated radiations from the inoculation point with
well-defined edges; morphotype C radiated uniformly from the
inoculation point and presented soft edges; morphotype D
displayed densely-grown stria with thick edges; and morphotype
E included the less abundant or unique morphotypes that
could not be included in the any of the other groups
(Supplementary Figure S1).
Killing Assays Using the C. elegans
Infection Model
The daily survival of the nematodes was scored during 15
consecutive days in order to obtain LT50 values of each isolate.
Determination of the LT50 values presented, once more, ample
intra-species variability (Figure 5A). Nevertheless, all isolates
could be easily grouped into two distinct clusters according to
their LT50 values. Those considered as virulent presented LT50
values ranging from 0.48 to 1.90 days and those included in
the non-virulent group showed LT50 values ranging from 4.10
to 8.19 days. In view of these results, an LT50 cut-off value of
3 days was selected to differentiate virulent (LT50< 3 days) from
non-virulent isolates (LT50 > 3 days). All A. baumannii isolates
were included within the non-virulent cluster, presenting LT50
values ranging from 4.85 to 8.04 days. A. nosocomialis was also
shown to be an overall non-virulent species under this model,
with 87.5% of isolates included in the non-virulent cluster and a
median LT50 value of 4.65 days. On the other hand, according to
this model, A. lactucae turned out to be the most virulent species
(median LT50 of 0.871 days), with only one isolate included
in the non-virulent group (Figure 5A). Of note, this was the
only isolate of A. lactucae that carried a carbapenemase gene. In
terms of virulence, A. lactucae presented significant differences in
virulence only with A. baumannii (Kruskal–Wallis test, post hoc
P-value< 0.001).
Interestingly, A. pittii and A. seifertii, when considered as a
whole, showed very large dispersion of the data and presented
no significant differences compared to either A. baumannii or
A. lactucae (Figure 5A). However, A. pittii and A. seifertii
FIGURE 5 | In vivo virulence of the Ab group species using the C. elegans
infection model. Overlapping dot plot and box plot of (A) the overall LT50
values of each species; (B) the LT50 values of each species splitting A. pittii
and A. seifertii in virulent (LT50 < 3 days) and non-virulent (LT50 > 3 days)
subgroups; (C) the biofilm formation values at 28◦C; and (D) the
surface-associated motility values of A. pittii isolates divided into virulent and
non-virulent subgroups. The boxes span from the first to the third quartile. The
median is indicated as a segment inside the box. Whiskers indicate the
minimum and maximum LT50 (A,B), biofilm formation values (C) and diameter
(D). Each dot corresponds to the average phenotype value for an isolate after
at least three biological replicates. Statistically significant differences between
species (Kruskal–Wallis test) and subgroup species (Mann–Whitney U-test)
are highlighted with asterisks: (∗) if the P-value < 0.05, (∗∗) if the
P-value < 0.01, and (∗∗∗) if the P-value < 0.001.
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isolates could be clearly divided into virulent (with LT50
values comparable to those of A. lactucae) and non-virulent
subgroups (with LT50 values similar to those of A. baumannii
and A. nosocomialis). When considered as independent groups,
the virulent isolates of both A. pittii and A. seifertii presented
significant differences in terms of virulence when compared to
A. baumannii (Kruskal–Wallis test, post hoc P-value< 0.001 and
0.011, respectively), and the non-virulent isolates also presented
significant differences when compared to A. lactucae (Kruskal–
Wallis test, post hoc P-value < 0.001 and 0.001, respectively)
(Figure 5B). Pairwise comparisons of the growth rates at
25◦C between the different species showed that there were
no differences in the growth rates between A. baumannii and
A. pittii/A. seifertii (Student’s t-test, P-value 0.521 and 0.122,
respectively). In addition, evaluation of the fitness rates at 25◦C
in all the species showed that there was no significant correlation
between the LT50 values and the growth rates at 25◦C of the
isolates (Spearman’s correlation coefficient−0.349, P-value 0.12),
and no differences in the growth rates at 25◦C were found
when the non-virulent and virulent isolates were compared as
two independent groups (Student’s t-test, P-value 0.217), thus
suggesting that the outcome of the killing assays was not affected
by the growth rate of the isolates at 25◦C.
In view of these results, we wondered if there were
intra-species differences between the virulent and non-virulent
subgroups of A. pittii and A. seifertii in regard to the
other virulence-related phenotypes studied above, i.e., biofilm
formation and motility, instead of considering these species as
a whole. In A. pittii, isolates included within the virulent group
were also shown to produce more biofilm at 28◦C as well as
to be more motile than those isolates included in the non-
virulent group (Figures 5C,D, Mann–Whitney U-test, P-value of
0.038 and 0.002, respectively). In A. seifertii, however, it was not
possible to associate virulent and non-virulent isolates with any
other phenotype as there were no significant differences between
both groups.
DISCUSSION
Despite the phenotypic similarities that hinder an accurate
identification at the species level of the members of the Ab
group using conventional identification methods, here we have
sought any relevant differences among them in terms of antibiotic
susceptibility patterns and virulence potential. Our efforts are
aimed at reinforcing the idea that reporting and studying them
collectively may be misleading in the clinical setting, as infections
caused by different members of the Ab group might have
substantially different clinical implications, as it has been noted
for A. pittii and A. nosocomialis but has not yet been thoroughly
examined for A. lactucae and A. seifertii (Chuang et al., 2011;
Chusri et al., 2014).
In terms of antimicrobial resistance, results from our study
are in good agreement with those of previous investigations
reporting overall less susceptibility to most antimicrobial agents
in A. baumannii, while A. pittii and A. nosocomialis tended
to be more susceptible (Chuang et al., 2011; Lai et al., 2012;
Chen et al., 2018; Pailhories et al., 2018). Studies that report
on the antimicrobial susceptibility of A. seifertii or A. lactucae,
on the other hand, are almost non-existent, since both species
have only recently been described. Nevertheless, a study by
Karah et al. (2011) included 3 A. seifertii isolates that were
susceptible to all antibiotics tested. Another report that identified
28/287 bloodstream A. seifertii isolates detected two carbapenem-
resistant isolates with a MDR phenotype, including resistance to
colistin (Park et al., 2012). Although some authors have claimed
that A. seifertii might be intrinsically resistant to polymyxins
(Cayo et al., 2016; Narciso et al., 2017), we did not find colistin-
resistant isolates of this species among our collection. Indeed, our
results suggest that the novel members of the Ab group might be
susceptible to most antibiotics, resembling other non-baumannii
Acinetobacter species.
Another characteristic of many Acinetobacter species is the
carriage of naturally occurring oxacillinases, such as OXA-51 in
A. baumannii, and it is widely accepted that members of the
same Acinetobacter species seem to harbor OXA allelic variants
that belong to the same OXA group (Perichon et al., 2014).
Such intrinsic OXA groups may account for β-lactam resistance,
especially when insertion sequences are found upstream from
the blaOXA gene (Higgins et al., 2010a). Nevertheless, bacterial
isolates belonging to A. nosocomialis and A. seifertii might be an
exception since no intrinsic OXAs have yet been found in the
genome sequences of A. nosocomialis and A. seifertii (Perichon
et al., 2014), except for the presence of plasmid-borne intrinsic
OXA from A. baumannii (Lee et al., 2012). In our study, also
in good agreement with data from Perichon et al. (2014), we
confirmed the presence of species-specific intrinsic OXA genes
in A. baumannii, A. lactucae and A. pittii, and the lack of them in
A. nosocomialis and A. seifertii (Figure 2).
The prevalence of adeB in A. baumannii from our collection
was high (93.75%) albeit within the range of previous reports
(53–97%) (Chu et al., 2006; Nemec et al., 2007; Lin et al., 2009;
Rajamohan et al., 2010; Modarresi et al., 2015; Nowak et al.,
2015), but we acknowledge that isolates of A. baumannii in our
study are the least polyclonal of all five species (Supplementary
Data Sheet S1), although it is not clear what was the degree of
clonality in previous studies. Interestingly, the adeB gene was
present in all the A. nosocomialis isolates as well as in many
A. lactucae and A. pittii isolates, confirming that this eﬄux system
is not restricted to A. baumannii (Espinal et al., 2011). Likewise,
the adeIJK and adeFGH operons were previously considered
as being highly specific of A. baumannii, and adeDE as being
specific of A. pittii. Here we have shown that adeJ and adeG
genes are present in all species, and that adeE was present in
all A. nosocomialis isolates and was detected among A. seifertii
and A. lactucae, although it was missing in A. baumannii. Hou
et al. (2012) reported a small number of A. baumannii isolates
harboring adeE together with adeB, albeit species identification
was performed with phenotypic methods which we now know
may lead to misidentification.
The study of virulence-related phenotypes revealed that
biofilm formation and surface-associated motility remained
highly variable among isolates from the same species. Indeed,
several authors have pointed out that the variability observed
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in biofilm formation might be due to this phenotype being
clone-specific (Rodriguez-Baño et al., 2008; Wroblewska et al.,
2008; de Breij et al., 2010; Giannouli et al., 2013; Kaliterna and
Goic-Barisic, 2013; Gentile et al., 2014), unfortunately, there
is still little knowledge regarding the population structure of
Acinetobacter species other than A. baumannii and thus, it is
not possible to compare major clonal groups for each of these
species. In addition, and as previously described forA. baumannii
(McQueary et al., 2012), we observed that motile isolates
displayed different surface-associated morphotypes, which were
not species-dependent but, again, strain-specific. Nonetheless,
despite the intra-species variability observed, we were still able
to find overall inter-species differences. In fact, the ability
to produce biofilm not only differed between species but
it was also temperature-dependent. Temperature modulation
of biofilm formation, as well as motility and antibiotic
resistance, have been previously observed in A. baumannii ATCC
17978, although the underlying regulatory mechanisms remain
unclear (De Silva et al., 2018). Our results suggest different
thermoregulation strategies of biofilm formation between isolates
of A. baumannii, A. nosocomialis, and A. seifertii and those of
A. lactucae and A. pittii.
Infection assays using the C. elegans animal model also
revealed overall differences between isolates of A. baumannii
and A. nosocomialis, being mostly non-virulent, and those of
A. lactucae, being highly virulent, although statistical significance
was only achieved between A. baumannii and A. lactucae. The
infection assays highlight the existence of two subpopulations
within our collection of A. pittii and A. seifertii isolates. It
remains unclear whether this observation represents the intrinsic
heterogeneity within each species, or it is an indication that the
taxonomic delineation for these two species needs to be further
investigated. It is worth mentioning that A. lactucae isolates were
previously classified as “A. pittii-like” (Espinal et al., 2015), since
both species are closely related, and the A. pittii taxon seems
to be taxonomically difficult as it contains several related (“-
like”) strains with no clear phenotypic/genotypic discontinuities
(Perichon et al., 2014; Mari-Almirall et al., 2017). It is also
plausible that our results reflect a process of adaptation to a
particular ecological niche, such as the human host.
To summarize, we observed that species which are more
related to the nosocomial environment, i.e., A. baumannii and
A. nosocomialis, had non-virulent phenotypes assessed in the
C. elegans infection model and tended to form less biofilm than
the other species. In contrast, A. pittii, which is more ecologically
diverse (Al Atrouni et al., 2016), showed greater virulence,
together with the two recently described species A. lactucae
and A. seifertii (Nemec et al., 2015; Mari-Almirall et al., 2017).
Interestingly, the only study that so far attempted to compare
the virulence traits of the different species of the Ab group
(A. lactucae was not included) also reported that A. seifertii
isolated from bloodstream infections showed enhanced in vitro
virulence properties (Na et al., 2016).
These findings however, do not seem to correlate with clinical
studies, where infections caused by A. baumannii in particular
but also by A. nosocomialis seem to be associated with a less
favorable outcome than that of patients with infections caused
by other species (Lee et al., 2011; Wisplinghoff et al., 2012;
Chusri et al., 2014; Lee et al., 2014; Fitzpatrick et al., 2015).
There are a few studies that suggest that such observation might
not be due to a higher pathogenicity of the former species
and rather be the consequence of inappropriate early empirical
treatment, since a higher proportion of A. baumannii infections
are caused by MDR strains.
The underlying question we intended to address here is
whether the novel Acinetobacter species present a higher
pathogenicity potential than A. baumannii that may be currently
masked by their overall antimicrobial susceptibility. If so, should
we expect worse clinical outcomes upon the acquisition of
resistance by these Acinetobacter species? Under this assumption,
A. nosocomialis and A. baumannii might have suffered a
reduction of intra-species diversity (population bottleneck)
resulting from adaptation to the human host and/or antibiotic
selection, while the variability observed among isolates ofA. pittii,
A. seifertii and A. lactucae might reflect their emergence and
distinct degrees of adaptation as human nosocomial pathogens
(Schleicher et al., 2013; Jain et al., 2016; Chen et al., 2018;
Pailhories et al., 2018; Rocha et al., 2018). Nevertheless, it is
important to acknowledge that the results provided in our study
arise from the usage of in vitro and nematode infection models
that do not entirely reflect more complex clinical scenarios
and, thus, the extrapolation of these results to infer virulence
in the human host must be taken with extreme caution. For
instance, respiratory tract infections and in particular both
community-acquired as well as nosocomial pneumonia are
mainly attributed to A. baumannii and A. nosocomialis while
there is little evidence that the other species are capable
of causing such infections in humans (Wang et al., 2013;
Larcher et al., 2017).
With the recent advances in bacterial identification methods
it is likely that the number of reported infections caused
by the novel species of Acinetobacter increases over time.
This increase should provide more robust clinical data to
evaluate the characteristics of infections caused by the different
members of the Ab group and reveal their pathogenic potential
in the human host.
DATA AVAILABILITY STATEMENT
The authors state that the dataset and partial protein sequences
supporting the findings of this study are available within the
article and its Supplementary Material.
AUTHOR CONTRIBUTIONS
CC, LR, PH, HS, IR, and JV collected the strains. CC, HS, IR, and
JV conceived and designed the experiments. CC, CR, MM-A, LR,
and PH performed the experiments. CC, CR, MM-A, PH, HS,
IR, and JV analyzed and interpreted the data. CC, PH, HS, IR,
and JV wrote the manuscript. All authors critically revised the
manuscript for intellectual content and read and approved the
final manuscript.
Frontiers in Microbiology | www.frontiersin.org 9 October 2019 | Volume 10 | Article 2429
fmicb-10-02429 October 22, 2019 Time: 17:48 # 10
Cosgaya et al. Acinetobacter spp., Virulence and Resistance
FUNDING
This study was supported by Planes Nacionales de I+D+i
2008–2011/2013–2016, Instituto de Salud Carlos III,
Subdirección General de Redes y Centros de Investigación
Cooperativa, Ministerio de Economía y Competitividad,
Spanish Network for Research in Infectious Diseases (REIPI
RD16/0016/0010); the 2017 call for Strategic Action on
Health (PI17/01932 and PI17/01468), co-financed by European
Development Regional Fund “A way to achieve Europe” and
operative program Intelligent Growth 2014–2020; and grant
2017 SGR 0809 from the Departament d’Universitats, Recerca
i Societat de la Informació of the Generalitat de Catalunya. CC
and MM-A were supported by grants FPU 13/02564 and FPU
14/06357, respectively, from the Spanish Ministry of Education,
Culture and Sports. IR was supported by the Department of
Health, Generalitat de Catalunya, grant SLT002/16/00349. Part
of the data has been presented as poster communications at the
10th International Symposium on the Biology of Acinetobacter,
3rd–5th June 2015, Athens (Greece), and at the XXVII European
Congress of Clinical Microbiology and Infectious Diseases
(ECCMID), 22nd–25th April 2017, Vienna (Austria).
ACKNOWLEDGMENTS
We thank all the isolates donors listed in Supplementary
Data Sheet S1 for kindly providing the isolates that made
possible this work.
SUPPLEMENTARY MATERIAL




Al Atrouni, A., Joly-Guillou, M. L., Hamze, M., and Kempf, M. (2016). Reservoirs
of non-baumannii Acinetobacter species. Front. Microbiol. 7:49. doi: 10.3389/
fmicb.2016.00049
Bitrian, M., Solari, C. M., Gonzalez, R. H., and Nudel, C. B. (2012). Identification
of virulence markers in clinically relevant strains of Acinetobacter genospecies.
Int. Microbiol. 15, 79–88. doi: 10.2436/20.1501.01.161
Bogaerts, P., Rezende de Castro, R., de Mendonca, R., Huang, T. D., Denis,
O., and Glupczynski, Y. (2013). Validation of carbapenemase and extended-
spectrum beta-lactamase multiplex endpoint PCR assays according to ISO
15189. J. Antimicrob. Chemother. 68, 1576–1582. doi: 10.1093/jac/dkt065
Cayo, R., Rodrigues-Costa, F., Pereira Matos, A., Godoy Carvalhaes, C.,
Dijkshoorn, L., and Gales, A. C. (2016). Old clinical isolates of Acinetobacter
seifertii in Brazil producing OXA-58. Antimicrob. Agents Chemother. 60, 2589–
2591. doi: 10.1128/aac.01957-15
Chen, L., Yuan, J., Xu, Y., Zhang, F., and Chen, Z. (2018). Comparison of
clinical manifestations and antibiotic resistances among three genospecies of
the Acinetobacter calcoaceticus-Acinetobacter baumannii complex. PLoS One
13:e0191748. doi: 10.1371/journal.pone.0191748
Chu, Y. W., Chau, S. L., and Houang, E. T. (2006). Presence of active eﬄux
systems AdeABC, AdeDE and AdeXYZ in different Acinetobacter genomic
DNA groups. J. Med. Microbiol. 55, 477–478. doi: 10.1099/jmm.0.46433-0
Chuang, Y. C., Sheng, W. H., Li, S. Y., Lin, Y. C., Wang, J. T., Chen, Y. C.,
et al. (2011). Influence of genospecies of Acinetobacter baumannii complex on
clinical outcomes of patients with acinetobacter bacteremia. Clin. Infect. Dis. 52,
352–360. doi: 10.1093/cid/ciq154
Chusri, S., Chongsuvivatwong, V., Rivera, J. I., Silpapojakul, K., Singkhamanan,
K., McNeil, E., et al. (2014). Clinical outcomes of hospital-acquired infection
with Acinetobacter nosocomialis and Acinetobacter pittii. Antimicrob. Agents
Chemother. 58, 4172–4179. doi: 10.1128/aac.02992-14
Cosgaya, C., Mari-Almirall, M., Van Assche, A., Fernandez-Orth, D., Mosqueda,
N., Telli, M., et al. (2016). Acinetobacter dijkshoorniae sp. nov., a member
of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex mainly
recovered from clinical samples in different countries. Int. J. Syst. Evol.
Microbiol. 66, 4105–4111. doi: 10.1099/ijsem.0.001318
de Breij, A., Dijkshoorn, L., Lagendijk, E., van der Meer, J., Koster, A., Bloemberg,
G., et al. (2010). Do biofilm formation and interactions with human cells
explain the clinical success of Acinetobacter baumannii? PLoS One 5:e10732.
doi: 10.1371/journal.pone.0010732
De Silva, P. M., Chong, P., Fernando, D. M., Westmacott, G., and Kumar, A. (2018).
Effect of incubation temperature on antibiotic resistance and virulence factors
of Acinetobacter baumannii ATCC 17978. Antimicrob. Agents Chemother. 62,
e1514–e1517. doi: 10.1128/aac.01514-17
Diancourt, L., Passet, V., Nemec, A., Dijkshoorn, L., and Brisse, S. (2010). The
population structure of Acinetobacter baumannii: expanding multiresistant
clones from an ancestral susceptible genetic pool. PLoS One 5:e10034.
doi: 10.1371/journal.pone.0010034
Edgar, R. C. (2004). MUSCLE: multiple sequence alignment with high accuracy and
high throughput. Nucleic Acids Res. 32, 1792–1797. doi: 10.1093/nar/gkh340
Espinal, P., Mosqueda, N., Telli, M., van der Reijden, T., Rolo, D., Fernandez-Orth,
D., et al. (2015). Identification of NDM-1 in a putatively novel Acinetobacter
species (“NB14”) closely related to Acinetobacter pittii. Antimicrob. Agents
Chemother. 59, 6657–6660. doi: 10.1128/aac.01455-15
Espinal, P., Pantel, A., Rolo, D., Marti, S., Lopez-Rojas, R., Smani, Y., et al.
(2019). Relationship between different resistance mechanisms and virulence in
Acinetobacter baumannii. Microb. Drug Resist. 25, 752–760. doi: 10.1089/mdr.
2018.0182
Espinal, P., Roca, I., and Vila, J. (2011). Clinical impact and molecular basis of
antimicrobial resistance in non-baumannii Acinetobacter. Future Microbiol. 6,
495–511. doi: 10.2217/fmb.11.30
Fitzpatrick, M. A., Ozer, E., Bolon, M. K., and Hauser, A. R. (2015).
Influence of ACB complex genospecies on clinical outcomes in a U.S.
hospital with high rates of multidrug resistance. J. Infect. 70, 144–152. doi:
10.1016/j.jinf.2014.09.004
Fitzpatrick, M. A., Ozer, E. A., and Hauser, A. R. (2016). Utility of whole-genome
sequencing in characterizing Acinetobacter epidemiology and analyzing
hospital outbreaks. J. Clin. Microbiol. 54, 593–612. doi: 10.1128/jcm.01818-15
Gentile, V., Frangipani, E., Bonchi, C., Minandri, F., Runci, F., and Visca, P. (2014).
Iron and Acinetobacter baumannii biofilm formation. Pathogens 3, 704–719.
doi: 10.3390/pathogens3030704
Giannouli, M., Antunes, L. C., Marchetti, V., Triassi, M., Visca, P., and Zarrilli,
R. (2013). Virulence-related traits of epidemic Acinetobacter baumannii strains
belonging to the international clonal lineages I-III and to the emerging
genotypes ST25 and ST78. BMC Infect. Dis. 13:282. doi: 10.1186/1471-2334-
13-282
Gundi, V. A., Dijkshoorn, L., Burignat, S., Raoult, D., and La Scola, B. (2009).
Validation of partial rpoB gene sequence analysis for the identification of
clinically important and emerging Acinetobacter species. Microbiology 155,
2333–2341. doi: 10.1099/mic.0.026054-0
Harding, C. M., Hennon, S. W., and Feldman, M. F. (2018). Uncovering the
mechanisms of Acinetobacter baumannii virulence. Nat. Rev. Microbiol. 16,
91–102. doi: 10.1038/nrmicro.2017.148
Higgins, P. G., Dammhayn, C., Hackel, M., and Seifert, H. (2010a). Global spread of
carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 65,
233–238. doi: 10.1093/jac/dkp428
Higgins, P. G., Lehmann, M., Wisplinghoff, H., and Seifert, H. (2010b).
gyrB multiplex PCR to differentiate between Acinetobacter calcoaceticus and
Frontiers in Microbiology | www.frontiersin.org 10 October 2019 | Volume 10 | Article 2429
fmicb-10-02429 October 22, 2019 Time: 17:48 # 11
Cosgaya et al. Acinetobacter spp., Virulence and Resistance
Acinetobacter genomic species 3. J. Clin. Microbiol. 48, 4592–4594. doi: 10.1128/
jcm.01765-10
Hou, P. F., Chen, X. Y., Yan, G. F., Wang, Y. P., and Ying, C. M. (2012). Study of the
correlation of imipenem resistance with eﬄux pumps AdeABC, AdeIJK, AdeDE
and AbeM in clinical isolates of Acinetobacter baumannii. Chemotherapy 58,
152–158. doi: 10.1159/000335599
Jain, A. L., Harding, C. M., Assani, K., Shrestha, C. L., Haga, M., Leber, A., et al.
(2016). Characteristics of invasive Acinetobacter species isolates recovered in a
pediatric academic center. BMC Infect. Dis. 16:346. doi: 10.1186/s12879-016-
1678-9
Kaliterna, V., and Goic-Barisic, I. (2013). The ability of biofilm formation in clinical
isolates of Acinetobacter baumannii belonging to two different European clones
causing outbreaks in the Split University Hospital, Croatia. J. Chemother. 25,
60–62. doi: 10.1179/1973947812y.0000000052
Karah, N., Haldorsen, B., Hegstad, K., Simonsen, G. S., Sundsfjord, A., and
Samuelsen, O. (2011). Species identification and molecular characterization
of Acinetobacter spp. blood culture isolates from Norway. J. Antimicrob.
Chemother. 66, 738–744. doi: 10.1093/jac/dkq521
Kinsella, R. L., Lopez, J., Palmer, L. D., Salinas, N. D., Skaar, E. P., Tolia, N. H.,
et al. (2017). Defining the interaction of the protease CpaA with its type II
secretion chaperone CpaB and its contribution to virulence in Acinetobacter
species. J. Biol. Chem. 292, 19628–19638. doi: 10.1074/jbc.M117.808394
Lai, C. C., Hsu, H. L., Tan, C. K., Tsai, H. Y., Cheng, A., Liu, C. Y., et al. (2012).
Recurrent bacteremia caused by the Acinetobacter calcoaceticus-Acinetobacter
baumannii complex. J. Clin. Microbiol. 50, 2982–2986. doi: 10.1128/jcm.01
194-12
Larcher, R., Pantel, A., Arnaud, E., Sotto, A., and Lavigne, J. P. (2017). First report
of cavitary pneumonia due to community-acquiredAcinetobacter pittii, study of
virulence and overview of pathogenesis and treatment. BMC Infect. Dis. 17:477.
doi: 10.1186/s12879-017-2589-0
Lee, H. Y., Chen, C. L., Wu, S. R., Huang, C. W., and Chiu, C. H. (2014).
Risk factors and outcome analysis of Acinetobacter baumannii complex
bacteremia in critical patients.Crit. CareMed. 42, 1081–1088. doi: 10.1097/ccm.
0000000000000125
Lee, Y. C., Huang, Y. T., Tan, C. K., Kuo, Y. W., Liao, C. H., Lee, P. I., et al.
(2011). Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3
bacteraemia: comparison of clinical features, prognostic factors and outcomes.
J. Antimicrob. Chemother. 66, 1839–1846. doi: 10.1093/jac/dkr200
Lee, Y. T., Kuo, S. C., Chiang, M. C., Yang, S. P., Chen, C. P., Chen, T. L.,
et al. (2012). Emergence of carbapenem-resistant non-baumannii species of
Acinetobacter harboring a blaOXA-51-like gene that is intrinsic to A. baumannii.
Antimicrob. Agents Chemother. 56, 1124–1127. doi: 10.1128/aac.00622-11
Lee, Y. T., Kuo, S. C., Yang, S. P., Lin, Y. T., Chiang, D. H., Tseng, F. C.,
et al. (2013). Bacteremic nosocomial pneumonia caused by Acinetobacter
baumannii and Acinetobacter nosocomialis: a single or two distinct clinical
entities? Clin. Microbiol. Infect. 19, 640–645. doi: 10.1111/j.1469-0691.2012.
03988.x
Lin, L., Ling, B. D., and Li, X. Z. (2009). Distribution of the multidrug eﬄux
pump genes, adeABC, adeDE and adeIJK, and class 1 integron genes in
multiple-antimicrobial-resistant clinical isolates of Acinetobacter baumannii-
Acinetobacter calcoaceticus complex. Int. J. Antimicrob. Agents 33, 27–32. doi:
10.1016/j.ijantimicag.2008.06.027
Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E.,
Giske, C. G., et al. (2012). Multidrug-resistant, extensively drug-resistant
and pandrug-resistant bacteria: an international expert proposal for interim
standard definitions for acquired resistance. Clin. Microbiol. Infect. 18, 268–281.
doi: 10.1111/j.1469-0691.2011.03570.x
Mari-Almirall, M., Cosgaya, C., Higgins, P. G., Van Assche, A., Telli, M.,
Huys, G., et al. (2017). MALDI-TOF/MS identification of species from the
Acinetobacter baumannii (Ab) group revisited: inclusion of the novel A. seifertii
and A. dijkshoorniae species. Clin. Microbiol. Infect. 23, 210.e1–210.e9. doi:
10.1016/j.cmi.2016.11.020
McQueary, C. N., Kirkup, B. C., Si, Y., Barlow, M., Actis, L. A., Craft, D. W.,
et al. (2012). Extracellular stress and lipopolysaccharide modulate Acinetobacter
baumannii surface-associated motility. J. Microbiol. 50, 434–443. doi: 10.1007/
s12275-012-1555-1
Modarresi, F., Azizi, O., Shakibaie, M. R., Motamedifar, M., Valibeigi, B., and
Mansouri, S. (2015). Effect of iron on expression of eﬄux pump (adeABC)
and quorum sensing (luxI, luxR) genes in clinical isolates of Acinetobacter
baumannii. APMIS 123, 959–968. doi: 10.1111/apm.12455
Na, I. Y., Chung, E. S., Jung, C. Y., Kim, D. H., Shin, J., Kang, K., et al.
(2016). Comparison of the virulence-associated phenotypes of five species
of Acinetobacter baumannii complex. J. Microbiol. Biotechnol. 26, 171–179.
doi: 10.4014/jmb.1507.07076
Narciso, A. C., Martins, W., Cayo, R., Pereira de Matos, A., Santos, S. V.,
Ramos, P. L., et al. (2017). Detection of OXA-58-producing Acinetobacter
seifertii recovered from a black-necked Swan at a Zoo Lake. Antimicrob. Agents
Chemother. 61:e01360-17. doi: 10.1128/aac.01360-17
Nemec, A., Krizova, L., Maixnerova, M., Sedo, O., Brisse, S., and Higgins,
P. G. (2015). Acinetobacter seifertii sp. nov., a member of the Acinetobacter
calcoaceticus-Acinetobacter baumannii complex isolated from human clinical
specimens. Int. J. Syst. Evol. Microbiol. 65, 934–942. doi: 10.1099/ijs.0.000043
Nemec, A., Maixnerova, M., van der Reijden, T. J., van den Broek, P. J.,
and Dijkshoorn, L. (2007). Relationship between the AdeABC eﬄux
system gene content, netilmicin susceptibility and multidrug resistance
in a genotypically diverse collection of Acinetobacter baumannii strains.
J. Antimicrob. Chemother. 60, 483–489. doi: 10.1093/jac/dkm231
Nowak, J., Seifert, H., and Higgins, P. G. (2015). Prevalence of eight resistance-
nodulation-division eﬄux pump genes in epidemiologically characterized
Acinetobacter baumannii of worldwide origin. J. Med. Microbiol. 64, 630–635.
doi: 10.1099/jmm.0.000069
Nowak, J., Zander, E., Stefanik, D., Higgins, P. G., Roca, I., Vila, J., et al. (2017).
High incidence of pandrug-resistant Acinetobacter baumannii isolates collected
from patients with ventilator-associated pneumonia in Greece, Italy and Spain
as part of the MagicBullet clinical trial. J. Antimicrob. Chemother. 72, 3277–
3282. doi: 10.1093/jac/dkx322
Pailhories, H., Tiry, C., Eveillard, M., and Kempf, M. (2018). Acinetobacter pittii
isolated more frequently than Acinetobacter baumannii in blood cultures: the
experience of a French hospital. J. Hosp. Infect. 99, 360–363. doi: 10.1016/j.jhin.
2018.03.019
Park, Y. K., Jung, S. I., Park, K. H., Kim, S. H., and Ko, K. S. (2012).
Characteristics of carbapenem-resistant Acinetobacter spp. other than
Acinetobacter baumannii in South Korea. Int. J. Antimicrob. Agents 39, 81–85.
doi: 10.1016/j.ijantimicag.2011.08.006
Peleg, A. Y., de Breij, A., Adams, M. D., Cerqueira, G. M., Mocali, S., Galardini,
M., et al. (2012). The success of Acinetobacter species; genetic, metabolic and
virulence attributes. PLoS One 7:e46984. doi: 10.1371/journal.pone.0046984
Peleg, A. Y., Seifert, H., and Paterson, D. L. (2008). Acinetobacter baumannii:
emergence of a successful pathogen. Clin. Microbiol. Rev. 21, 538–582. doi:
10.1128/cmr.00058-07
Perichon, B., Goussard, S., Walewski, V., Krizova, L., Cerqueira, G., Murphy, C.,
et al. (2014). Identification of 50 class D beta-lactamases and 65 Acinetobacter-
derived cephalosporinases in Acinetobacter spp. Antimicrob. Agents Chemother.
58, 936–949. doi: 10.1128/aac.01261-13
Rajamohan, G., Srinivasan, V. B., and Gebreyes, W. A. (2010). Novel role of
Acinetobacter baumannii RND eﬄux transporters in mediating decreased
susceptibility to biocides. J. Antimicrob. Chemother. 65, 228–232. doi: 10.1093/
jac/dkp427
Roca, I., Espinal, P., Vila-Farres, X., and Vila, J. (2012). The Acinetobacter
baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant
menace. Front. Microbiol. 3:148. doi: 10.3389/fmicb.2012.00148
Rocha, G. A., Lima, D. F., Rodrigues, E. R., Leao, R. S., Folescu, T. W., Firmida,
M. C., et al. (2018). Species distribution, sequence types and antimicrobial
resistance of Acinetobacter spp. from cystic fibrosis patients. Epidemiol. Infect.
146, 524–530. doi: 10.1017/s0950268817002849
Rodriguez-Baño, J., Marti, S., Soto, S., Fernandez-Cuenca, F., Cisneros, J. M.,
Pachon, J., et al. (2008). Biofilm formation in Acinetobacter baumannii:
associated features and clinical implications. Clin. Microbiol. Infect. 14,
276–278. doi: 10.1111/j.1469-0691.2007.01916.x
Schleicher, X., Higgins, P. G., Wisplinghoff, H., Korber-Irrgang, B., Kresken,
M., and Seifert, H. (2013). Molecular epidemiology of Acinetobacter
baumannii and Acinetobacter nosocomialis in Germany over a 5-year period
(2005-2009). Clin. Microbiol. Infect. 19, 737–742. doi: 10.1111/1469-0691.
12026
Seifert, H., Dolzani, L., Bressan, R., van der Reijden, T., van Strijen, B., Stefanik,
D., et al. (2005). Standardization and interlaboratory reproducibility assessment
Frontiers in Microbiology | www.frontiersin.org 11 October 2019 | Volume 10 | Article 2429
fmicb-10-02429 October 22, 2019 Time: 17:48 # 12
Cosgaya et al. Acinetobacter spp., Virulence and Resistance
of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter
baumannii. J. Clin. Microbiol. 43, 4328–4335. doi: 10.1128/jcm.43.9.4328-4335.
2005
Skiebe, E., de Berardinis, V., Morczinek, P., Kerrinnes, T., Faber, F., Lepka, D.,
et al. (2012). Surface-associated motility, a common trait of clinical isolates
of Acinetobacter baumannii, depends on 1,3-diaminopropane. Int. J. Med.
Microbiol. 302, 117–128. doi: 10.1016/j.ijmm.2012.03.003
Tamura, K., Stecher, G., Peterson, D., Filipski, A., and Kumar, S. (2013). MEGA6:
molecular evolutionary genetics analysis version 6.0. Mol. Biol. Evol. 30,
2725–2729. doi: 10.1093/molbev/mst197
Vaneechoutte, M., Dijkshoorn, L., Tjernberg, I., Elaichouni, A., de Vos, P., Claeys,
G., et al. (1995). Identification of Acinetobacter genomic species by amplified
ribosomal DNA restriction analysis. J. Clin. Microbiol. 33, 11–15.
Wang, X., Chen, T., Yu, R., Lu, X., and Zong, Z. (2013). Acinetobacter pittii
and Acinetobacter nosocomialis among clinical isolates of the Acinetobacter
calcoaceticus-baumannii complex in Sichuan, China. Diagn. Microbiol. Infect.
Dis. 76, 392–395. doi: 10.1016/j.diagmicrobio.2013.03.020
Wisplinghoff, H., Paulus, T., Lugenheim, M., Stefanik, D., Higgins, P. G.,
Edmond, M. B., et al. (2012). Nosocomial bloodstream infections due to
Acinetobacter baumannii, Acinetobacter pittii and Acinetobacter nosocomialis
in the United States. J. Infect. 64, 282–290. doi: 10.1016/j.jinf.2011.12.008
Wroblewska, M. M., Sawicka-Grzelak, A., Marchel, H., Luczak, M., and
Sivan, A. (2008). Biofilm production by clinical strains of Acinetobacter
baumannii isolated from patients hospitalized in two tertiary care hospitals.
FEMS Immunol. Med. Microbiol. 53, 140–144. doi: 10.1111/j.1574-695X.2008.
00403.x
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2019 Cosgaya, Ratia, Marí-Almirall, Rubio, Higgins, Seifert, Roca and
Vila. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original author(s) and the copyright owner(s)
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 12 October 2019 | Volume 10 | Article 2429
